One Year Later, Mallinckrodt Divestment Options Still Open For Tyco
This article was originally published in The Gray Sheet
Executive Summary
Tyco Healthcare's reluctance to divest its Mallinckrodt subsidiary's pharmaceutical business one year after acquiring the parent company may reflect in part the market potential of partner Palatin Technologies' LeuTech infection imaging agent, for which Mallinckrodt has exclusive marketing and distribution rights.
You may also be interested in...
Bristol Gains Imaging Agent Pipeline Via DuPont Pharmaceuticals Acquisition
Bristol-Myers Squibb's acquisition of DuPont Pharmaceuticals includes an R&D pipeline of two imaging agents, one of which is pending at FDA, and a radiotherapeutic.
Palatin LeuTech Diagnostic Cost-Effectiveness Analysis Under Way
Palatin Technologies is conducting a cost effectiveness analysis to support use of LeuTech to aid in the diagnosis of equivocal appendicitis.
Palatin's LeuTech Clinically Useful For Appendicitis Diagnosis - FDA Panel
Clinical management decisions on whether to use computed tomography (CT) or Palatin's LeuTech imaging agent for detecting appendicitis in patients with equivocal appendicitis likely will depend on an institution's level of expertise with each modality.